Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.
A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.
Obesity has a major impact on health and its economic cost could be up €1. 5 billion a year, according to HSE figures ...
Until now, the drugs have only been available from specialist NHS clinics or private pharmacies, costing around £150 to £200 ...
As a result, it will be available only on private prescription at a cost of €215 or more a month. That equates to an annual ...
Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...
Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...
While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.
The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been ... from private pharmacies with a doctor's prescription. However, the high cost of these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback